BASEL, SWITZERLAND, April 24, 2025 /EINPresswire.com/ — The new guidelines for the use of monoclonal antibodies (mAbs) published in Neurodegenerative Diseases, serve as exemplary clinical recommendations for clinicians and healthcare providers, supporting the advancement of Alzheimer’s disease treatment in Switzerland.
